[The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer].

Abstract

This clinical trial was designed to evaluate the efficacy and safety of indisetron hydrochloride an oral 5-HT3 receptor antagonist, for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer with paclitaxel/ carboplatin or docetaxel/carboplatin. Indisetron hydrochloride(8 mg)was administered orally to 46 gynecologic cancer patients at 0.5 hours before administration of the above chemotherapy agents. Number of patients who showed nausea or vomiting for 24 hours was counted. The complete vomiting inhibition rate at 24 hours after chemotherapy was 89.1%(41/46), and nausea inhibition rate was 71.7%(33/46). No serious adverse events were observed. These findings indicate that prophylactic administration of indisetron hydrochloride is safe and useful for inhibition of nausea/vomiting caused by cancer chemotherapy.

• Authors: Kimio Ushijima, Norio Wake, Hiroaki Kobayashi, Toru Hachisuga, Naoyuki Toki, Hideaki Masuzaki, Kohei Kotera, Tatsuhiko Kawarabayashi, Makoto Emoto, Toshiharu Kamura
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 35 Issue 7 Pg. 1169-73 (Jul 2008) ISSN: 0385-0684 [Print] Japan
• PMID: 18633256 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Bridged-Ring Compounds
• Pyrazoles
• indisetron hydrochloride

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Bridged-Ring Compounds (adverse effects, therapeutic use)
• Drug-Related Side Effects and Adverse Reactions
• Female
• Genital Neoplasms, Female (drug therapy)
• Humans
• Middle Aged
• Nausea (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Pyrazoles (adverse effects, therapeutic use)
• Vomiting (drug therapy)